Johnson & Johnson
JNJ · What the business does, what can go wrong, and how options sellers approach it
What it does
Johnson & Johnson is a large, diversified healthcare company. It operates through two main businesses: Innovative Medicine (prescription drugs) and MedTech (devices and tools used in surgery and other medical specialties).
A former consumer health business was separated into an independent company, so JNJ now focuses on pharmaceuticals and medical technology.
How it makes money
In Innovative Medicine, JNJ develops and sells branded drugs, with major focus areas in immunology, oncology and neurology. Revenue comes from selling these drugs to wholesalers, hospitals, pharmacies and health systems, often under patent protection.
In MedTech, it sells devices, surgical equipment and related products to hospitals and clinics. These sales are tied to procedure volumes.
Both businesses sell globally, though the United States is the largest single market.
Why investors own it
- Diversification: Drugs and devices rely on different demand drivers, which can soften the impact of trouble in any one product.
- Dividend record: JNJ has a long history of paying and raising its dividend, and is often viewed as a defensive, income-oriented holding.
- Scale: Its size supports sustained research spending across many programs.
- Index membership: It is a long-standing member of the S&P 500.
What can go wrong
- Patent expirations: When a top drug loses exclusivity, cheaper copies can take sales quickly.
- Drug pricing pressure: Government policy and insurer negotiations can limit what the company earns on medicines.
- Litigation: The company has faced large product liability and legal claims, which can bring costly settlements and headline risk.
- Trial and approval risk: Pipeline drugs can fail in testing or be rejected by regulators.
- Currency and regulation: Global sales expose it to exchange rates and differing rules.
What to watch
- Segment sales growth in Innovative Medicine and MedTech
- Clinical trial readouts and regulatory decisions
- Patent expiry dates for major products
- Litigation developments
- Dividend announcements and annual guidance
Options income angle
Options on JNJ are generally liquid, with active near-term expirations and tight spreads at common strikes. Its implied volatility has tended to be relatively low compared with many individual stocks, often rising around earnings, major trial results, regulatory rulings and litigation news.
One caution: a court ruling or failed trial can move the stock sharply, and a short put or covered call offers little protection against a large drop.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 28, 2025, filed February 11, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
Johnson & Johnson grew worldwide sales 6.0% to $94.2 billion in 2025, and pre-tax earnings nearly doubled to $32.6 billion from $16.7 billion. Much of that jump came from reversing about $7.0 billion of talc lawsuit reserves rather than from operations. The filing also shows STELARA, a large drug, losing sales to biosimilars (copycat versions of biologic drugs), more debt after an acquisition, and a planned separation of the Orthopaedics business.
How the business did
- Sales growth came from volume of 8.4%, with price subtracting 3.1%. Oncology sales were $25.4 billion, up 22.1%, led by DARZALEX at $14,351 million.
- STELARA sales fell 41.3% to $6,078 million because of biosimilar competition and Medicare Part D redesign. Immunology overall fell 11.8%.
- MedTech sales were $33.8 billion, up 6.1%. Cardiovascular grew 15.8%, helped by the Shockwave acquisition, while Orthopaedics grew only 1.1%.
- Profit before tax was helped by the talc reserve reversal, against about $5.1 billion of talc charges in 2024. Management also recorded an expense of $0.8 billion for the Auris shareholder litigation.
- Operations generated $24.5 billion of cash. The company paid $12.4 billion in dividends, repurchased $6.0 billion of stock, and spent $17.5 billion on acquisitions, mainly Intra-Cellular (CAPLYTA). Total debt rose to $47.9 billion from $36.6 billion.
Risks specific to this company
- Talc litigation: The company is a defendant in numerous lawsuits over talc body powders, primarily JOHNSON'S Baby Powder. It carries a talc reserve of approximately $3.4 billion, and the filing says payouts could exceed accruals.
- Patent and generic losses: STELARA biosimilars are expected to keep launching globally. At least two biosimilars are pursuing U.S. approval against SIMPONI, and generic competition for OPSUMIT is expected in 2026. Each could significantly reduce sales.
- Government drug pricing: The Inflation Reduction Act subjects certain products to government-set pricing beginning in 2026. Janssen's constitutional challenge continues, and in December 2025 it asked the U.S. Supreme Court for review.
- Wholesaler concentration: Three wholesalers accounted for approximately 21.8%, 15.5% and 11.1% of total gross revenues.
- Separation of Orthopaedics: The filing says the separation may not finish on the planned terms or timeline, if at all. It also says the costs will be significant.
- Trade and international exposure: About 43% of sales are outside the U.S. The filing cites tariffs, China volume-based procurement (government bulk-buying that pushes prices down), and operations in Argentina, Turkey, Venezuela and Egypt treated as highly inflationary.
What management is watching
- The Orthopaedics separation is targeted for completion within 18 to 24 months after the October 2025 announcement. Management intends to explore multiple paths to carry it out.
- A Surgery restructuring has estimated total costs of $0.9 billion - $1.0 billion and is expected to be substantially completed by the end of fiscal year 2026.
- Innovation is central. Products introduced in the past five years made up approximately 25% of 2025 sales, and research and development spending was $14.7 billion. Several filings and approvals are in progress, including TREMFYA indications and ICOTYDE for psoriasis.
- On funding, management points to operating cash flow, committed credit lines and a new 364-day $10 billion credit facility expiring June 24, 2026. It does not foresee any significant incremental liquidity risk.
- Investors are pointed to operational growth, which excludes currency effects. A 1% change in the U.S. dollar against foreign currencies would move translated sales by approximately $0.4 billion. The company raised its dividend for the 63rd consecutive year and declared $1.30 per share in January 2026.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 27, 2026, filed October 21, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
Johnson & Johnson's sales kept growing in the fiscal third quarter, but reported pre-tax earnings nearly vanished. The cause was a charge of approximately $5.5 billion for the proposed talc ovarian litigation resolution, plus $1.0 billion of acquired in-process research and development (R&D bought through the Firefly Bio deal). Underneath, cancer and neuroscience drugs grew strongly while STELARA kept losing sales to biosimilars (cheaper copies of a biologic drug).
How the business did
- Sales: Third-quarter worldwide sales were $25.4 billion, up 5.9%, with operational growth of 6.0%. Operational growth strips out the effect of currency swings. STELARA's decline reduced worldwide operational growth by approximately 4.2%. For the nine months, sales were $74.8 billion, up 7.4%.
- Profit: Third-quarter earnings before taxes were $34.0 million, or 0.1% of sales, versus $7.5 billion, or 31.2% of sales, a year earlier. Nine-month earnings before taxes were $12.8 billion versus $27.6 billion, and the prior year included approximately $7.0 billion from a talc reserve reversal.
- Segments: Innovative Medicine (prescription drugs) sales were $16.8 billion, up 7.7%. TREMFYA reached $2,396 million, and STELARA fell to $716 million from $1,570 million. MedTech sales were $8.6 billion, up 2.5%. Surgery declined, which management tied to China volume-based procurement and Middle East disruptions.
- Cash and capital return: Nine-month operating cash flow was $18.9 billion. The company paid $9.6 billion in dividends and spent $6.0 billion repurchasing stock. Debt was $44.6 billion, against cash and marketable securities of approximately $17.2 billion. A regular dividend of $1.34 per share was declared on October 13, 2026.
What management is watching
- Drug patent losses: The filing expects STELARA biosimilars to keep hurting sales. SIMPONI biosimilars entered Europe in the second quarter of 2026, with a potential U.S. entrant later in 2026. OPSUMIT faced U.S. generics late in the second quarter of 2026, and potential generic entrants in 2027 could hit UPTRAVI and XARELTO. Management says these will likely reduce future sales.
- Restructuring and separation: The company plans to separate its Orthopaedics business by mid-2027. A supply chain restructuring program has estimated costs between $0.7 billion and $0.8 billion and is expected to be substantially complete by the end of 2029.
- Cash commitments: Management expects operating cash flow and borrowing capacity to cover a remaining balance of approximately $9.0 billion related to talc matters, approximately $2.6 billion for the option to acquire Sail, and approximately $0.9 billion for opioid settlements.
- Pricing and trade: Management points to U.S. drug pricing initiatives, tariffs, and its revised 340B policies (the federal program requiring drug discounts to certain providers) as ongoing influences.
Follow JNJ in Kortex
The Kortex app shows JNJ's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.